Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/243727
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampSouza, Philipi Coutinho dept_BR
dc.contributor.authorunicampBarbosa-Souza, Valériapt_BR
dc.contributor.authorunicampHyslop, Stephenpt_BR
dc.contributor.authorunicampAnhê, Gabriel Foratopt_BR
dc.contributor.authorunicampSchenka, André Almeidapt_BR
dc.typeArtigopt_BR
dc.titleDecreased expression of stem cell markers by simvastatin in 7,12- dimethylbenz(a)anthracene (dmba)-induced breast cancerpt_BR
dc.contributor.authorRennó, André Lisboapt_BR
dc.contributor.authorAlves-Júnior, Marcos Josépt_BR
dc.contributor.authorRocha, Rafael Malagolipt_BR
dc.contributor.authorSouza, Philipi Coutinho dept_BR
dc.contributor.authorSouza, Valéria Barbosa dept_BR
dc.contributor.authorJampietro, Julianopt_BR
dc.contributor.authorVassallo, Josépt_BR
dc.contributor.authorHyslop, Stephenpt_BR
dc.contributor.authorAnhê, Gabriel Foratopt_BR
dc.contributor.authorSchenka, Natália Guimarães de Moraespt_BR
dc.contributor.authorSoares, Fernando Augustopt_BR
dc.contributor.authorSchenka, André Almeidapt_BR
dc.subjectCélulas-tronco neoplásicaspt_BR
dc.subjectSinvastatinapt_BR
dc.subject.otherlanguageNeoplastic stem cellspt_BR
dc.subject.otherlanguageSimvastatinpt_BR
dc.description.abstractSimvastatin, a competitive inhibitor of HMG-CoA reductase widely used in the treatment and prevention of hyperlipidemia-related diseases, has recently been associated to in vitro anticancer stem cell (CSC) actions. However, these effects have not been confirmed in vivo. To assess in vivo anti-CSC effects of simvastatin, female Sprague-Dawley rats with 7,12-dimethyl-benz(a)anthracene (DMBA)-induced mammary cancer and control animals were treated for 14 days with either simvastatin (20 or 40 mg/kg/day) or soybean oil (N = 60). Tumors and normal breast tissues were removed for pathologic examination and immunodetection of CSC markers. At 40 mg/kg/day, simvastatin significantly reduced tumor growth and the expression of most CSC markers. The reduction in tumor growth (80%) could not be explained solely by the decrease in CSCs, since the latter accounted for less than 10% of the neoplasia (differentiated cancer cells were also affected). Stem cells in normal, nonneoplastic breast tissues were not affected by simvastatin. Simvastatin was also associated with a significant decrease in proliferative activity but no increase in cell death. In conclusion, this is the first study to confirm simvastatin anti-CSC actions in vivo, further demonstrating that this effect is specific for neoplastic cells, but not restricted to CSCs, and most likely due to inhibition of cell proliferation.en
dc.description.abstractSimvastatin, a competitive inhibitor of HMG-CoA reductase widely used in the treatment and prevention of hyperlipidemia-related diseases, has recently been associated to in vitro anticancer stem cell (CSC) actions. However, these effects have not been confirmed in vivo. To assess in vivo anti-CSC effects of simvastatin, female Sprague-Dawley rats with 7,12-dimethyl-benz(a)anthracene (DMBA)-induced mammary cancer and control animals were treated for 14 days with either simvastatin (20 or 40 mg/kg/day) or soybean oil (N = 60). Tumors and normal breast tissues were removed for pathologic examination and immunodetection of CSC markers. At 40 mg/kg/day, simvastatin significantly reduced tumor growth and the expression of most CSC markers. The reduction in tumor growth (80%) could not be explained solely by the decrease in CSCs, since the latter accounted for less than 10% of the neoplasia (differentiated cancer cells were also affected). Stem cells in normal, nonneoplastic breast tissues were not affected by simvastatin. Simvastatin was also associated with a significant decrease in proliferative activity but no increase in cell death. In conclusion, this is the first study to confirm simvastatin anti-CSC actions in vivo, further demonstrating that this effect is specific for neoplastic cells, but not restricted to CSCs, and most likely due to inhibition of cell proliferationpt
dc.relation.ispartofToxicologic pathologypt_BR
dc.relation.ispartofabbreviationToxicol. pathol.pt_BR
dc.publisher.cityThousand Oaks, CApt_BR
dc.publisher.countryEstados Unidospt_BR
dc.publisherSagept_BR
dc.date.issued2015pt_BR
dc.date.monthofcirculationApr.pt_BR
dc.identifier.citationDecreased Expression Of Stem Cell Markers By Simvastatin In 7,12-dimethylbenz(a)anthracene (dmba)-induced Breast Cancer. Sage Publications Inc, v. 43, p. 400-410 APR-2015.pt_BR
dc.language.isoengpt_BR
dc.description.volume43pt_BR
dc.description.issuenumber3pt_BR
dc.description.firstpage400pt_BR
dc.description.lastpage410pt_BR
dc.rightsfechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn0192-6233pt_BR
dc.identifier.eissn1533-1601pt_BR
dc.identifier.doi10.1177/0192623314544707pt_BR
dc.identifier.urlhttps://journals.sagepub.com/doi/10.1177/0192623314544707pt_BR
dc.description.sponsorshipFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOpt_BR
dc.description.sponsorshipCAPES - COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL E NÍVEL SUPERIORpt_BR
dc.description.sponsorship1FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOpt_BR
dc.description.sponsorship1CAPES - COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL E NÍVEL SUPERIORpt_BR
dc.description.sponsordocumentnumberFAPESP [Fapesp]pt
dc.description.sponsordocumentnumber2010/10703-0pt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.date.available2016-06-07T13:33:32Z-
dc.date.accessioned2016-06-07T13:33:32Z-
dc.description.provenanceMade available in DSpace on 2016-06-07T13:33:32Z (GMT). No. of bitstreams: 1 wos_000353148900008.pdf: 1921194 bytes, checksum: d4c041abb06dbc28510134e4d92350b8 (MD5) Previous issue date: 2015en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/243727-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.identifier.source25341428-
dc.creator.orcidsem informaçãopt_BR
dc.creator.orcidsem informaçãopt_BR
dc.creator.orcid0000-0002-9293-3638pt_BR
dc.creator.orcid0000-0003-1543-4154pt_BR
dc.creator.orcidsem informaçãopt_BR
dc.type.formArtigo originalpt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
wos_000353148900008.pdf1.88 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.